scholarly journals In Vivo Gene Transfer Using a Nonprimate Lentiviral Vector Pseudotyped with Ross River Virus Glycoproteins

2002 ◽  
Vol 76 (18) ◽  
pp. 9378-9388 ◽  
Author(s):  
Yubin Kang ◽  
Colleen S. Stein ◽  
Jason A. Heth ◽  
Patrick L. Sinn ◽  
Andrea K. Penisten ◽  
...  

ABSTRACT Vectors derived from lentiviruses provide a promising gene delivery system. We examined the in vivo gene transfer efficiency and tissue or cell tropism of a feline immunodeficiency virus (FIV)-based lentiviral vector pseudotyped with the glycoproteins from Ross River Virus (RRV). RRV glycoproteins were efficiently incorporated into FIV virions, generating preparations of FIV vector, which after concentration attain titers up to 1.5 × 108 TU/ml. After systemic administration, RRV-pseudotyped FIV vectors (RRV/FIV) predominantly transduced the liver of recipient mice. Transduction efficiency in the liver with the RRV/FIV was ca. 20-fold higher than that achieved with the vesicular stomatitis virus G protein (VSV-G) pseudotype. Moreover, in comparison to VSV-G, the RRV glycoproteins caused less cytotoxicity, as determined from the levels of glutamic pyruvic transaminase and glutamic oxalacetic transaminase in serum. Although hepatocytes were the main liver cell type transduced, nonhepatocytes (mainly Kupffer cells) were also transduced. The percentages of the transduced nonhepatocytes were comparable between RRV and VSV-G pseudotypes and did not correlate with the production of antibody against the transgene product. After injection into brain, RRV/FIV preferentially transduced neuroglial cells (astrocytes and oligodendrocytes). In contrast to the VSV-G protein that targets predominantly neurons, <10% of the brain cells transduced with the RRV pseudotyped vector were neurons. Finally, the gene transfer efficiencies of RRV/FIV after direct application to skeletal muscle or airway were also examined and, although transgene-expressing cells were detected, their proportions were low. Our data support the utility of RRV glycoprotein-pseudotyped FIV lentiviral vectors for hepatocyte- and neuroglia-related disease applications.

2002 ◽  
Vol 24 (3) ◽  
pp. 196-201 ◽  
Author(s):  
Lingyun Cheng ◽  
Sunan Chaidhawangul ◽  
Flossie Wong-Staal ◽  
James Gilbert ◽  
Eric Poeschla ◽  
...  

2002 ◽  
Vol 61 (1) ◽  
pp. S32-S36 ◽  
Author(s):  
G. Luca Gusella ◽  
Elena Fedorova ◽  
Daniele Marras ◽  
Paul E. Klotman ◽  
Mary E. Klotman

2006 ◽  
Vol 81 (2) ◽  
pp. 539-547 ◽  
Author(s):  
Andreas Pichlmair ◽  
Sandra S. Diebold ◽  
Stephen Gschmeissner ◽  
Yasuhiro Takeuchi ◽  
Yasuhiro Ikeda ◽  
...  

ABSTRACT Recombinant lentiviral vectors (LVs) are commonly used as research tools and are being tested in the clinic as delivery agents for gene therapy. Here, we show that Vesicular stomatitis virus G protein (VSV-G)-pseudotyped LV preparations produced by transient transfection are heavily contaminated with tubulovesicular structures (TVS) of cellular origin, which carry nucleic acids, including the DNA plasmids originally used for LV generation. The DNA carried by TVS can act as a stimulus for innate antiviral responses, triggering Toll-like receptor 9 and inducing alpha/beta interferon production by plasmacytoid dendritic cells (pDC). Removal of TVS markedly reduces the ability of VSV-G-pseudotyped LV preparations to activate pDC. Conversely, virus-free TVS are sufficient to stimulate pDC and act as potent adjuvants in vivo, eliciting T- and B-cell responses to coadministered proteins. These results highlight the role of by-products of virus production in determining the immunostimulatory properties of recombinant virus preparations and suggest possible strategies for diminishing responses to LVs in gene therapy and in research use.


2008 ◽  
Vol 40 (2) ◽  
pp. 278
Author(s):  
Irina Nifontova ◽  
Daria Svinareva ◽  
Natalia Sats ◽  
Vadim Surin ◽  
Nina Drize

2005 ◽  
Vol 40 (12) ◽  
pp. 1817-1821 ◽  
Author(s):  
Erik D. Skarsgard ◽  
Louis Huang ◽  
Stacy C. Reebye ◽  
Adam Y. Yeung ◽  
William W. Jia

2006 ◽  
Vol 13 ◽  
pp. S63
Author(s):  
Minna U. Kaikkonen ◽  
Jani K. Raty ◽  
Kari J. Airenne ◽  
Thomas Wirth ◽  
Tommi Heikura ◽  
...  

Gene Therapy ◽  
2005 ◽  
Vol 13 (4) ◽  
pp. 304-312 ◽  
Author(s):  
M U Kaikkonen ◽  
J K Räty ◽  
K J Airenne ◽  
T Wirth ◽  
T Heikura ◽  
...  

2006 ◽  
Vol 14 (4) ◽  
pp. 514-524 ◽  
Author(s):  
D. Nicole Worsham ◽  
Todd Schuesler ◽  
Christof von Kalle ◽  
Dao Pan

2008 ◽  
Vol 16 (2) ◽  
pp. 302-307 ◽  
Author(s):  
Anastasios Lymperopoulos ◽  
Giuseppe Rengo ◽  
Carmela Zincarelli ◽  
Stephen Soltys ◽  
Walter J Koch

Sign in / Sign up

Export Citation Format

Share Document